We are developing cutting-edge cell therapies and antibody-based medicines
for the treatment of liver diseases.

people die of chronic or cirrhotic liver diseases each year in US
patients were on the waiting list for a liver transplantation in the US in 2016
liver transplants were reported in the US in 2016

At Promethera® Biosciences, we are pioneering the development of liver stem cell therapies to help patients in need of liver transplantation to restore liver health.

Our passion translates into a commitment to holistically change patients’ lives by developing liver therapies for unmet medical needs, but also by providing high quality education about liver disease and how to prevent it through healthy lifestyle choices.

We are developing groundbreaking treatments for end-stage liver disease.

HepaStem is our most advanced cell-based therapy and has the potential to deliver novel treatment options for chronic and acute liver diseases, especially for decompensated cirrhosis in late-stage such as Acute-on-Chronic Liver Failure (ACLF) and Non-Alcoholic SteatoHepatitis (NASH), as well as fibrosis.

At Promethera® Biosciences, we are striving to be the global leader in regenerative medicine and cell therapy for liver diseases.

Our broad intellectual property portfolio includes a proprietary antibody therapy, a human organ and cell sourcing, as well as outstanding manufacturing capabilities. It brings a unique set of technological assets, exclusive IP and know-how.

Restoring Liver Health

Twitter feed

Our #collaborations are crucial to our #success. We partner with leading organizations across the world that enable us to streamline our #innovative portfolio.
Check out our website for more info:

We look forward to presenting at #OnHelix20 hosted by @OneNucleus on July 13-14 as part of the @BioWin_asbl cluster. Learn more about the event at http://www.onhelix.com/

Patients that are unlucky enough to develop #ACLF have a low chance of survival. Currently, the only way to save these patients' lives is by replacing the damaged liver via transplantation. More info on /what-we-do/our-science/